Study design and simulation approach

Handbook of Experimental Pharmacology

Volumn 205, Issue , 2011, Pages 125-148

  Läer, Stephanie ^a   Meibohm, Bernd ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Bottom up; Children; Modeling; Simulation; Top down

Indexed keywords

ALFENTANIL; AMLODIPINE; ENALAPRIL; FOSINOPRIL; IRBESARTAN; LEVOFLOXACIN; LOSARTAN; MORPHINE; PARACETAMOL; SOTALOL; TEDUGLUTIDE; THEOPHYLLINE;

ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL SIMULATION; COMPARTMENT MODEL; COMPUTER PROGRAM; DETERMINISTIC SIMULATION; DRUG RESEARCH; GROUPS BY AGE; HUMAN; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; MODELING AND SIMULATION; MONTE CARLO METHOD; PEDIATRICS; PHARMACEUTICAL CARE; PHYSICAL CHEMISTRY; PHYSIOLOGICAL PROCESS; PHYSIOLOGY BASED PHARMACOKINETIC MODELING; PRIORITY JOURNAL; PROBLEM SOLVING; RECOMMENDED DRUG DOSE; SIMULATION; SINGLE DRUG DOSE; STUDY DESIGN; VIRTUAL WORD SIMULATION;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG EVALUATION; EPIDEMIOLOGIC RESEARCH DESIGN; HUMAN DEVELOPMENT; HUMANS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGICAL PHENOMENA; SAMPLE SIZE; SOFTWARE;

EID: 80054945958     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-20195-0_6     Document Type: Article

References (32)

1. Alcorn J, McNamara PJ (2003) Pharmacokinetics in the newborn. Adv Drug Deliv Rev 55:667-686 (Pubitemid 36428679)
2. Andrew MA, Hebert MF, Vicini P (2008) Physiologically based pharmacokinetic model of midazolam disposition during pregnancy. Conf Proc IEEE Eng Med Biol Soc 54:54-57
3. Arant BS Jr (1978) Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr 92:705-712 (Pubitemid 8301704)
4. Bartelink IH, Rademaker CM, Schobben AF et al (2006) Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45:1077-1097 (Pubitemid 44631388)
5. Benjamin DK Jr, Smith PB, Jadhav P et al (2008) Pediatric antihypertensive trial failures: Analysis of end points and dose range. Hypertension 51:834-840 (Pubitemid 351654692)
6. Björkman S (2004) Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: Theophylline and midazolam as model drugs. Br J Clin Pharmacol 59:691-704 (Pubitemid 40835503)
7. Bonate PL (2000) Clinical trial simulation in drug development. Pharm Res 17:252-256 (Pubitemid 30225127)
8. Bouwmeester NJ, Anderson BJ, Tibboel D et al (2004) Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth 92:208-217 (Pubitemid 38159658)
9. Eddy DM, Schlessinger L (2003) Validation of the Archimedes diabetes model. Diabetes Care 26:3102-3110 (Pubitemid 37339505)
10. Edginton A, Willmann S (2008) Physiology-based simulations of a pathological condition: Prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet 47:743-752
11. Edginton A, Schmitt W, Willmann S (2006) Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 45:1013-1034 (Pubitemid 44436004)
12. El-Tahtawy A, Kokki H, Reidenberg BE (2006) Population pharmacokinetics of oxycodone in children 6 months to 7 years old. J Clin Pharmacol 46:433-442
13. Girard P (2005) Clinical trial simulation: A tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol 96:228-234 (Pubitemid 40388000)
14. Gobburu JV (2010) How to double success rate of pediatric trials? U.S. Food and Drug Administration, Office of Clinical Pharmacology, Silver Spring, MD, http://www.slideshare.net/JogaGobburu/how-to-double-success-rate-of- pediatric-trials. Accessed 17 Jun 2010
15. Hines RN (2008) The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118:250-267
16. Hsien L (2010) Identifying paediatric needs in cardiology and the prediction of sildenafil exposure in children with pulmonary arterial hypertension. PhD thesis at the Faculty of Mathematics and Sciences, University of Düsseldorf, Germany
17. Jadhav PR, Zhang J, Gobburu JV (2009) Leveraging prior quantitative knowledge in guiding pediatric drug development: A case study. Pharm Stat 8:216-224
18. Johnson TN, Rostami-Hodjegan A, Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45:931-956 (Pubitemid 44299829)
19. Khalil F, Laer S (2011) Physiologically based pharmacokinetic modeling: Methodology, applications, and limitations with a focus on its role in pediatric drug development. J Biomed Biotechnol. In press
20. Laer S, Wauer I, Behn F et al (2001) Pharmacokinetics of sotalol in different age groups of children with tachycardia. J Pediatr Pharmacol Ther 6:50-59
21. Laer S, Elshoff JP, Meibohm B et al (2005) Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 46:1322-1330 (Pubitemid 41615557)
22. Laer S, Barrett JS, Meibohm B (2009) The in silico child: Using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol 49:889-904
23. Li F, Nandy P, Chien S et al (2010) Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother 54:375-379
24. Meibohm B, Laer S, Panetta JC et al (2005) Population pharmacokinetic studies in pediatrics: Issues in design and analysis. AAPS J 7:E475-E487 (Pubitemid 43071326)
25. Morselli PL, Morselli-Franco R, Bossi L (1980) Clinical pharmacokinetics in newborns and infants. Clin Pharmacokinet 5:485-527
26. Mouksassi MS, Marier JF, Cyran J et al (2009) Clinical trial simulations in pediatric patients using realistic covariates: Application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin Pharmacol Ther 86:667-671
27. Schlessinger L, EddyDM(2002) Archimedes: A new model for simulating health care systems - the mathematical formulation. J Biomed Inform 35:37-50 (Pubitemid 35216430)
28. Sheiner LB, Ludden TM (1992) Population pharmacokinetics/dynamics. Ann Rev Pharmacol Toxicol 32:185-209
29. van der Marel CD, Anderson BJ, van Lingen RA et al (2003) Paracetamol and metabolite pharmacokinetics in infants. Eur J Clin Pharmacol 59:243-251 (Pubitemid 36995133)
30. Willlmann S (2009) The in silico child. Can computer simulations replace clinical pharmacokinetic studies? Pharm Unserer Zeit 38:62-67
31. Willmann S, Lippert J, SevestreMet al (2003) PK-Sim®: A physiologically based pharmacokinetic "whole-body" model. Biosilico 1:121-124 (Pubitemid 40416764)
32. Yared A, Ichikara I (1994) Glomerular circulation and function in paediatric nephrology. Williams and Wilkins, Baltimore